secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001493152-25-001069
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology enters $1.7M at-the-market sales agreement with WallachBeth Capital
--------------------------------------------------------------------------------

- Entered ATM sales agreement to sell up to $1.7M of common stock.
- Agent commission 3.5% of gross sales; up to $50K expense reimbursement.
- Net proceeds for working capital and development of lead compound LB-100.
- Sales at market prices on Nasdaq or other methods per Rule 415.
- Company not obligated to sell any shares under the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225001069/0001493152-25-001069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225001069/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer